NASDAQ:OLMA Olema Pharmaceuticals (OLMA) Stock Price, News & Analysis $10.65 -0.12 (-1.11%) Closing price 04:00 PM EasternExtended Trading$10.73 +0.08 (+0.76%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Olema Pharmaceuticals Stock (NASDAQ:OLMA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Olema Pharmaceuticals alerts:Sign Up Key Stats Today's Range$10.51▼$10.8850-Day Range$9.19▼$12.7752-Week Range$5.34▼$36.26Volume960,508 shsAverage Volume960,416 shsMarket Capitalization$931.88 millionP/E RatioN/ADividend YieldN/APrice Target$42.40Consensus RatingModerate Buy Company Overview Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California. Read More Olema Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScoreOLMA MarketRank™: Olema Pharmaceuticals scored higher than 39% of companies evaluated by MarketBeat, and ranked 693rd out of 909 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingOlema Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 11 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialOlema Pharmaceuticals has a consensus price target of $42.40, representing about 298.1% upside from its current price of $10.65.Amount of Analyst CoverageOlema Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Olema Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Olema Pharmaceuticals are expected to decrease in the coming year, from ($2.43) to ($2.72) per share.Price to Book Value per Share RatioOlema Pharmaceuticals has a P/B Ratio of 1.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted20.90% of the float of Olema Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverOlema Pharmaceuticals has a short interest ratio ("days to cover") of 18.21, which indicates bearish sentiment.Change versus previous monthShort interest in Olema Pharmaceuticals has recently increased by 5.70%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOlema Pharmaceuticals does not currently pay a dividend.Dividend GrowthOlema Pharmaceuticals does not have a long track record of dividend growth. News and Social Media1.5 / 5News Sentiment-0.52 News SentimentOlema Pharmaceuticals has a news sentiment score of -0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 19 news articles for Olema Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 2 people have searched for OLMA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Olema Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Olema Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $144,750.00 in company stock.Percentage Held by Insiders12.56% of the stock of Olema Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions91.78% of the stock of Olema Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Olema Pharmaceuticals' insider trading history. Receive OLMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Olema Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OLMA Stock News HeadlinesJPMorgan Chase & Co. Lowers Olema Pharmaceuticals (NASDAQ:OLMA) Price Target to $46.00August 15 at 2:42 AM | americanbankingnews.comHC Wainwright Has Negative Outlook for OLMA Q3 EarningsAugust 15 at 1:43 AM | americanbankingnews.comTrump’s “BIG MISTAKE” stock is still dirt cheapA U.S. energy producer operating across 3.7 million acres now pumps roughly 143,299 barrels of oil and 467 million cubic feet of natural gas daily, yet the entire business is valued at just 8 billion despite generating 3.2 billion in operating income. Wall Street institutions already hold about 88 percent of shares, and management has authorized a 40-million-share buyback, but most individual investors still don't know the company's name. As AI data centers strain the power grid, this producer's natural gas output could become increasingly valuable.August 18 at 1:00 AM | Monument Traders Alliance (Ad)Piper Sandler Reaffirms Their Buy Rating on Olema Pharmaceuticals (OLMA)August 13, 2026 | theglobeandmail.comOlema Oncology Appoints Jason O’Byrne as Chief Financial OfficerAugust 13, 2026 | markets.businessinsider.comOlema Pharmaceuticals (OLMA) Receives a Buy from Goldman SachsAugust 13, 2026 | theglobeandmail.comCitigroup Issues Pessimistic Forecast for Olema Pharmaceuticals (NASDAQ:OLMA) Stock PriceAugust 13, 2026 | americanbankingnews.comOlema Pharmaceuticals (NASDAQ:OLMA) Shares Gap Down Following Weak EarningsAugust 13, 2026 | americanbankingnews.comSee More Headlines OLMA Stock Analysis - Frequently Asked Questions How have OLMA shares performed this year? Olema Pharmaceuticals' stock was trading at $25.00 on January 1st, 2026. Since then, OLMA shares have decreased by 57.4% and is now trading at $10.65. How were Olema Pharmaceuticals' earnings last quarter? Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) issued its quarterly earnings data on Monday, August, 10th. The company reported ($0.61) earnings per share for the quarter, missing analysts' consensus estimates of ($0.55) by $0.06. When did Olema Pharmaceuticals IPO? Olema Pharmaceuticals (OLMA) raised $187 million in an IPO on Thursday, November 19th 2020. The company issued 11,000,000 shares at $16.00-$18.00 per share. J.P. Morgan, Jefferies, Cowen and Canaccord Genuity served as the underwriters for the IPO. Who are Olema Pharmaceuticals' major shareholders? Top institutional shareholders of Olema Pharmaceuticals include Jupiter Topco LLC (8.11%), BlackRock Inc. (7.69%), Hennion & Walsh Asset Management Inc. (0.48%) and Bank of America Corp DE (0.38%). Insiders that own company stock include Bain Capital Life Sciences Inv, Bvf Partners L P/Il, Biocapital Advisors L Paradigm, Cyrus Harmon, David C Myles, Sean Bohen, Shane William Charles Kovacs, Naseem Zojwalla, Shawnte Mitchell and Ian T Clark. View institutional ownership trends. How do I buy shares of Olema Pharmaceuticals? Shares of OLMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Olema Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Olema Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), e.l.f. Beauty (ELF) and Jabil (JBL). Company Calendar Last Earnings8/10/2026Today8/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 OLMA's financial health is in the Red zone, according to TradeSmith. OLMA has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:OLMA CIK1750284 Webwww.olema.com Phone650-243-5555FaxN/AEmployees70Year Founded2007Price Target and Rating Average Price Target for Olema Pharmaceuticals$42.40 High Price Target$59.00 Low Price Target$27.00 Potential Upside/Downside+298.1%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($2.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$162.45 million Net MarginsN/A Pretax MarginN/A Return on Equity-48.26% Return on Assets-43.04% Debt Debt-to-Equity Ratio0.01 Current Ratio8.86 Quick Ratio8.86 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.88 per share Price / Book1.81Miscellaneous Outstanding Shares87,500,000Free Float76,508,000Market Cap$931.88 million OptionableOptionable Beta2.03 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:OLMA) was last updated on 8/18/2026 by MarketBeat.com Staff. From Our PartnersThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredI’m sharing my top day trading secrets for freeA 30-year trading veteran who managed multi-million-dollar hedge funds and wealth for one of the world's riche...The TradingPub | SponsoredTrump’s “BIG MISTAKE” stock is still dirt cheapA U.S. energy producer operating across 3.7 million acres now pumps roughly 143,299 barrels of oil and 467 mil...Monument Traders Alliance | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThree oil giants buried the same discovery for 50 yearsIn 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...Behind the Markets | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Olema Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Olema Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
